Feed SMSMED.CO
Summary
33 / 100 · Bulios Score
Valuation 56Growth 57Profitability 5Quality 16Debt 34Stability 32
What speaks for it
- Revenue grew by 30% a year over the last 3 years.
- It has been profitable 6 years in a row.
What to watch
- Earnings per share fell by 87% a year over the last 3 years.
- Repaying its net debt would take 5.6 years of operating profit.
- Out of every 100 DKK of revenue, only 0.0 DKK is left as net profit.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedP/E against the industry (Medical - Devices)
P/E today 2,470.5 Industry median 20.8
Today you pay 2,470.5 DKK for 1 DKK of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (DKK)
2021202220232024202520262027
Diluted EPS (DKK)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 42% a year over 5 years. Over the last 3 years it grew by 30% a year. Earnings per share fell by 87% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments 1.45M kr
Debt 74.0M kr
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail